Interventional Antimicrobial Strategy for the Management of Infections in Neutropenic Patients with Hematologic Malignancies: Results of a Multi-Center Randomized Comparison of Antimicrobial Regiments

  • W. Hiddemann
  • H. Link
  • G. Maschmeyer
  • P. Meyer
  • M. Helmerking
  • J. Schmidt
  • D. Adam
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)


The increasing intensity of antineoplastic chemotherapy for hematologic malignancies within recent years regularly induces severe and prolonged myelosuppression. Thus, overall therapeutic success for treating these diseases has become substantially dependent on effective supportive measures and on the control of infectious complications, in particular. While in the 1960s and 70s resistance against cytostatic therapy accounted for the majority of treatment failures, severe infections nowadays comprise the predominant cause of lethal outcome. In acute myeloid leukemia for example, up to 40%–50% of cases, and especially older patients succumb to infectious complications during induction chemotherapy [1–3]. Hence, it has become common practice to immediately initiate broad spectrum parenteral antibiotic therapy upon the first appearance of fever or other clinical signs of infections in these patients. In addition, however, a prospective interventional strategy is required since a considerable proportion of patients experiences multiple infectious episodes during prolonged myelosuppression or resistance to first-lineantimicrobial therapy. Therefore, it was the aim of the Paul Ehrlich Society for Chemotherapy to evaluate an interventional antimicrobial strategy comprised of three consecutive therapeutic phases using a prospective randomized comparison of different antimicrobial regiments at each escalation step [4].


Neutropenic Patient Systemic Fungal Infection Documented Infection Lung Infiltrate Systemic Antifungal Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brown AE (1984) Neutropenia. fever, and infection. Am J Med 76: 421–4288PubMedCrossRefGoogle Scholar
  2. 2.
    Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1982) Causes of initial remission induction failure in acute myelogenous leukemia. Blood 60: 309–315PubMedGoogle Scholar
  3. 3.
    Büchner T, Hiddemann W (1990) Treatment strategies in acute myeloid leukemia (AML). Blut 60: 61–67CrossRefGoogle Scholar
  4. 4.
    Paul Ehrlich Society Group - Link H, Maschmeyer G, Meyer P, Hiddemann W, Helmerking M, Eisenmann E, Schmitt J, Adam D: Interventional antimicrobial strategy in febrile neutropenic patients with hematologic malignancies-results of a three step randomized multicenter study. Submitted for publicationGoogle Scholar
  5. 5.
    Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H and the European Organization for Research on Treatment of Cancer Antimicrobial Therapy Project Group (1986) Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 29: 263–270PubMedGoogle Scholar
  6. 6.
    Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, Rubin M, Skelton J, Thaler M, Wesley R (1986) A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315: 552–558PubMedCrossRefGoogle Scholar
  7. 7.
    The EORTC International Antimicrobial Therapy Cooperative Group (1987) Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. New Engl J Med 317: 1692–1698CrossRefGoogle Scholar
  8. 8.
    Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, Yow MD (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J infect Dis 161: 381–396PubMedCrossRefGoogle Scholar
  9. 9.
    Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG (1982) Empiric antihiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72: 101–111PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • W. Hiddemann
    • 1
  • H. Link
    • 2
  • G. Maschmeyer
    • 3
  • P. Meyer
    • 4
  • M. Helmerking
    • 5
  • J. Schmidt
    • 5
  • D. Adam
    • 6
  1. 1.Department of Hematology and OncologyUniversity of GöttingenGermany
  2. 2.Department of Hematology and OncologyMedical School of HannoverGermany
  3. 3.Department of MedicineEvangelisches Krankenhaus Essen-WerdenGermany
  4. 4.Department of Hematology and OncologyUniversity of WürzburgGermany
  5. 5.Paul-Ehrlich-Society Study CenterMünchenGermany
  6. 6.Department of PediatricsUniversity of MünchenGermany

Personalised recommendations